Julien De Wolf1, Jocelyn Bellier2, Francoise Lepimpec-Barthes3, Francois Tronc4, Christophe Peillon5, Alain Bernard6, Jean-Philippe Le Rochais7, Olivier Tiffet8, Edouard Sage2, Alain Chapelier2, Henri Porte1. 1. Department of Thoracic Surgery, Calmette Hospital, University Hospital of Lille, Lille, France. 2. Department of Thoracic Surgery, Foch Hospital, Suresnes, France. 3. Department of Thoracic Surgery, Georges Pompidou European Hospital, Paris, France. 4. Department of Thoracic and Cardiovascular Surgery, Louis Pradel Hospital, Hospices Civils de Lyon, Bron, France. 5. Department of General and Thoracic Surgery, Rouen University Hospital, Rouen, France. 6. Department of Thoracic and Cardiovascular Surgery, Dijon University Hospital, Dijon, France. 7. Department of Thoracic Surgery, Caen University Hospital, Caen, France. 8. Department of Thoracic Surgery, Saint-Etienne University Hospital, Saint-Etienne, France.
Abstract
OBJECTIVES: Adrenal oligometastatic non-small-cell lung cancer is rare, and surgical management remains controversial. METHODS: We performed a multicentre, retrospective study from January 2004 to December 2014. The main objective was to evaluate survival in patients who had undergone adrenalectomy after resection of primary lung cancer. Secondary objectives were to determine prognostic, survival and recurrence factors. RESULTS: Fifty-nine patients were included. Forty-six patients (78%) were men. The median age was 58 years [39-75 years]. Twenty-six cases (44%) showed synchronous presentation, and 33 cases (56%) had a metachronous presentation. The median time to onset of metastasis was 18.3 months [6-105 months]. The 5-year overall survival rate was 59%; the median survival time was 77 months [0.6-123 months]. A recurrence was observed in 70% of the population. Mediastinal lymph node invasion (P = 0.035) is a detrimental prognostic factor of survival. CONCLUSIONS: After exhaustive staging, patients with adrenal oligometastatic non-small-cell lung cancer benefit from bifocal surgery.
OBJECTIVES:Adrenal oligometastatic non-small-cell lung cancer is rare, and surgical management remains controversial. METHODS: We performed a multicentre, retrospective study from January 2004 to December 2014. The main objective was to evaluate survival in patients who had undergone adrenalectomy after resection of primary lung cancer. Secondary objectives were to determine prognostic, survival and recurrence factors. RESULTS: Fifty-nine patients were included. Forty-six patients (78%) were men. The median age was 58 years [39-75 years]. Twenty-six cases (44%) showed synchronous presentation, and 33 cases (56%) had a metachronous presentation. The median time to onset of metastasis was 18.3 months [6-105 months]. The 5-year overall survival rate was 59%; the median survival time was 77 months [0.6-123 months]. A recurrence was observed in 70% of the population. Mediastinal lymph node invasion (P = 0.035) is a detrimental prognostic factor of survival. CONCLUSIONS: After exhaustive staging, patients with adrenal oligometastatic non-small-cell lung cancer benefit from bifocal surgery.